Mounjaro (Tirzepatide) for Weight Loss: A UK Guide

Few medicines have entered the UK’s vocabulary as quickly as Mounjaro. In 2021 it was searched roughly 100 times a month; by 2025 that figure had climbed to around 905,000 — one of the steepest surges in interest any drug has ever recorded here. Around 1.5 million UK adults are now using weight-loss injections of one kind or another, the overwhelming majority paying privately, and Mounjaro sits at the centre of that shift.

This guide explains what Mounjaro actually is, how tirzepatide works, what the clinical trials genuinely showed, and the realities of accessing it in the UK. It is written to inform, not to promote. Mounjaro is a prescription-only medicine, and nothing here is a recommendation to take it. If you think it might be right for you, that conversation belongs with your GP or a pharmacist, who can assess your health and prescribe and monitor it safely.

What is Mounjaro?

Mounjaro is the brand name for tirzepatide, a once-weekly injection developed by Eli Lilly and given under the skin of the abdomen, thigh or upper arm. It is the only dual GIP/GLP-1 receptor agonist licensed for weight management in the UK, and it currently produces the highest average weight loss of any approved anti-obesity medication.

That “dual” mechanism is what sets it apart. Most weight-loss injections act on a single hormone pathway; tirzepatide acts on two. Understanding how these drugs work as a class is worth a read on its own — our overview of how GLP-1 weight-loss injections work covers the biology in plain English.

How tirzepatide works

Tirzepatide mimics two natural gut hormones at once — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Activating both receptors together produces:

• Greater appetite suppression than acting on GLP-1 alone, so people tend to feel full sooner and eat less
• Enhanced, glucose-dependent insulin release, which helps regulate blood sugar
• A favourable shift in body composition, with a high proportion of the weight lost coming from fat mass rather than muscle
• Improvements in lipid profiles and other cardiovascular risk markers

In short, it turns down appetite and hunger signals while helping the body manage glucose more efficiently. It is designed to be used alongside a reduced-calorie diet and increased physical activity — not instead of them.

What the SURMOUNT trials found

The evidence base for tirzepatide in obesity is the SURMOUNT programme, which enrolled more than 5,000 participants across six trials. The headline results come from SURMOUNT-1, in adults without type 2 diabetes.

The 22.5% average was described as “unprecedented” when published — the highest ever reported for a weight-loss drug in a pivotal registration trial. Body-composition analysis found roughly 75% of the weight lost was fat mass, with fat reduced by about 34% against a smaller reduction in lean tissue.

A few important caveats sit behind those numbers. In adults with type 2 diabetes (SURMOUNT-2), average weight loss was several percentage points lower — a consistent pattern across this class of drug. And SURMOUNT-4, which looked at what happens after initial success, found that people switched to placebo regained substantial weight, while those who kept taking tirzepatide held onto their results. That single finding shapes how the drug should be understood.

Tirzepatide is not a short course you finish and forget. The trial evidence points to it being an ongoing treatment: stop, and for most people the weight tends to return. What happens after stopping is a subject worth reading about in its own right — see our guide to what happens when you stop weight-loss injections.

Who is it licensed for?

Mounjaro was authorised by the MHRA for weight management in November 2023, and NICE recommended it for NHS use in December 2024. The approved criteria are, broadly:

• A BMI of 35 or above plus at least one weight-related health condition — such as type 2 diabetes, high blood pressure, raised cholesterol, obstructive sleep apnoea or cardiovascular disease
• Many private providers will consider a BMI of 30 or above
• Lower BMI thresholds apply for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, typically reduced by 2.5 kg/m²

It is not suitable during pregnancy or breastfeeding, for people with a personal or family history of medullary thyroid cancer or MEN2 syndrome, for those with severe gastrointestinal disease, or for type 1 diabetes. A prescriber checks all of this before treatment — which is precisely why it is not something to source casually online.

How you take it

Treatment starts low and builds slowly to let the body adjust. The starting dose is 2.5 mg once weekly, increasing every four weeks in steps — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, up to a maximum of 15 mg. If someone has lost less than 5% of their body weight after six months on the highest tolerated dose, guidance advises the prescriber to review whether it is worth continuing.

Accessing Mounjaro in the UK

Here the gap between demand and availability is stark. NHS access is real but heavily rationed:

• Specialist weight-management services have been able to prescribe it since March 2025, for people with a BMI of 35 or above plus a qualifying condition.
• GP prescribing began in a phased rollout from June 2025, initially limited to a BMI of 40 or above plus at least four qualifying conditions, widening gradually over several years.
• Around 3.4 million people in England are estimated to be eligible, yet the NHS aims to treat only about 220,000 in the first three years. Full rollout could take up to 12 years, and under 5% of eligible patients currently access it through the NHS.

That is why the private market is the main route for most users. As a rough guide, monthly private costs run from around £180 at the starting dose to roughly £270 at the top dose, putting a first year in the region of £2,600 to £3,000. Prices rose sharply in 2025 after Eli Lilly increased its list prices, and that jump prompted a notable shift of interest towards Wegovy — a drug we cover in our Wegovy (semaglutide) UK guide, which is a useful comparison if you are weighing up the options.

Side effects to understand

The most common side effects are gastrointestinal: nausea (reported by around 31% at the highest dose), diarrhoea, vomiting, reduced appetite and constipation. These tend to be most noticeable during dose increases and usually settle once a stable dose is reached. Reassuringly, roughly three in four people report no nausea or only mild, manageable symptoms.

Rarer but more serious risks include pancreatitis and gallbladder problems such as gallstones, the latter linked to rapid weight loss. There is also a black-box warning relating to thyroid tumours seen in animal studies, which underpins the contraindications above. This is the core reason the medicine is prescription-only and monitored: a clinician weighs these risks against the benefits for each individual.

The aesthetic side: ‘Mounjaro face’, loose skin and muscle loss

Because the weight comes off quickly, there are cosmetic trade-offs worth knowing about — ones that increasingly bring people to body clinics rather than their GP.

Facial volume loss, informally called “Mounjaro face” or “Ozempic face”, can leave the face looking gaunt or older as fat is lost from the cheeks. Loose skin may appear on the abdomen, arms and thighs after significant loss, particularly where the skin has less natural elasticity. And although tirzepatide preserves lean mass better than diet alone, roughly a quarter of the total weight lost is lean tissue, including muscle — which is why resistance training is strongly encouraged throughout.

None of these are medical emergencies, but they are real, and they are cosmetic rather than something the injection itself will fix. This is where non-surgical body contouring enters the picture — not as an alternative to weight loss, but as a way to refine the result afterwards. Skin-tightening and muscle-focused treatments are sometimes considered once weight has stabilised; our guide to combining weight-loss injections with body contouring explains where these approaches genuinely help and where they are oversold.

It is worth being clear on one point: Fat Reduction Bristol does not prescribe or supply weight-loss injections. What the clinic offers are non-surgical, body-contouring options — tools for shaping and firming specific areas once your weight is settled, not for weight loss itself.

A balanced view

Mounjaro is a genuinely significant development in obesity medicine, with trial results that outperform anything before it. But it is a serious, long-term medical treatment, not a shortcut — it needs the right candidate, proper supervision, ongoing commitment, and realistic expectations about both the benefits and the trade-offs.

If your goal is overall weight loss, the right first step is a conversation with your GP or pharmacist, who can assess your suitability properly. If, further down the line, you find yourself looking to address loose skin, lost tone or a specific area that weight loss alone has not resolved, that is where a body-contouring consultation can help. The team at Fat Reduction Bristol is happy to talk through your non-surgical options honestly and tell you what is — and is not — likely to make a difference for you.